

Chronic Fatigue Syndrome

REFERENCES

- Aaron LA, Burke MM et al. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. *Arch Intern Med* . 2000 Jan 24;160(2):221–7.
- Afari N, Buchwald D. Chronic fatigue syndrome: a review. *Am J Psychiatry* . 2003 Feb;160(2):221–36.
- Anonymous. Mismatched double-stranded RNA: polyI:polyC12U. *Drugs RD* . 2004;5(5):297–4
- Balch PA, Balch JF. *Prescription for Nutritional Healing* . 3rd ed. New York : Avery; 2000.
- Behan PO, Behan WM, et al. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. *Acta Neurol Scand* . 1990 Sep;82(3):209–16.
- Bentler SE, Hartz AJ, et al. Prospective observational study of treatments for unexplained chronic fatigue. *J Clin Psychiatry* . 2005 May;66(5):625–32.
- Borish L, Schmalting K, et al. Chronic fatigue syndrome: identification of distinct subgroups on the basis of allergy and psychologic variables. *J Allergy Clin Immunol* . 1998 Aug;102(2):222–30.
- Bou-Holaigah I, Rowe PC, et al. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. *JAMA* . 1995 Sep 27;274(12):961–7.
- Bounous G, Molson J. Competition for glutathione precursors between the immune system and the skeletal muscle: pathogenesis of chronic fatigue syndrome. *Med Hypotheses* . 1999 Oct;53(4):347–9.
- Bruno RL, Creange SJ, et al. Parallels between post-polio fatigue and chronic fatigue syndrome: a common pathophysiology? *Am J Med* . 1998 Sep 28;105(3A):66S–73S.
- Calkins H, Rowe PC. Relationship between chronic fatigue syndrome and neurally mediated hypotension. *Cardiol Rev* . 1998 May;6(3):125–34.
- Centers for Disease Control and Prevention (CDC). Available at: <http://www.cdc.gov/ncidod/diseases/cfs/about/demographics.htm>. Accessed November 2 , 2005a.
- Centers for Disease Control and Prevention (CDC). Available at: <http://www.cdc.gov/ncidod/diseases/cfs/>. Accessed November 2 , 2005b.
- Centers for Disease Control and Prevention (CDC). Available at: <http://www.cdc.gov/ncidod/diseases/cfs/about/what.htm>. Accessed November 2 , 2005c.
- Chronic Fatigue and Immune Disorder Syndrome (CFIDS) Association of America . Available at: www.cfids.org/resources/newly-diagnosed-faq.asp. Accessed October 5, 2005.
- Cleare AJ , Bearn J, et al. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. *J Affect Disord* . 1995 Aug 18;34(4):283–9.
- Cox IM, Campbell MJ, et al. Red blood cell magnesium and chronic fatigue syndrome. *Lancet* . 1991 Mar 30;337(8744):757–60.
- De Becker P, De Meirleir K, et al. Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome. *Horm Metab Res* . 1999 Jan;31(1):18-21.
- Demitrack MA. Chronic fatigue syndrome: a disease of the hypothalamic-pituitary-adrenal axis? *Ann Med* . 1994 Feb;26(1):1– 5.

Dimai HP, Porta S, et al. Daily oral magnesium supplementation suppresses bone turnover in young adult males. *J Clin Endocrinol Metab* . 1998 Aug;83(8):2742–8.

Droge W, Holm E. Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction. *FASEB J* . 1997 Nov;11(13):1077–89.

Evengard B, Klimas N. Chronic fatigue syndrome: probable pathogenesis and possible treatments. *Drugs* . 2002;62(17):2433–46.

Forsyth LM, Preuss HG, et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. *Ann Allergy Asthma Immunol* . 1999 Feb;82(2):185–91.

Fulle S, Mecocci P, et al. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. *Free Radic Biol Med* . 2000 Dec 15;29(12):1252–9.

Gerrity TR, Papanicolaou DA, et al. Immunologic aspects of chronic fatigue syndrome. Report on a research symposium convened by the CFIDS Association of America and co-sponsored by the US Centers for Disease Control and Prevention and the National Institutes of Health. *Neuroimmunomodulation* . 2004;11(6):351–7.

Gray JB, Martinovic AM. Eicosanoids and essential fatty acid modulation in chronic disease and the chronic fatigue syndrome. *Med Hypotheses* . 1994 Jul;43(1):31–42.

Grimble RF. Nutritional antioxidants and the modulation of inflammation: theory and practice. *New Horiz* . 1994;2(2):175–85.

Heap LC, Peters TJ, et al. Vitamin B status in patients with chronic fatigue syndrome. *J R Soc Med* . 1999 Apr;92(4):183–5.

Hendler SS, Rorvik D. *PDR for Nutritional Supplements* . 1st ed. Montvale , NJ : Thomson PDR; 2001.

Jacobson W, Saich T, et al. Serum folate and chronic fatigue syndrome. *Neurology* . 1993 Dec;43(12):2645–7.

Jamison JR. *Clinical Guide to Nutrition and Dietary Supplements in Disease Management* . Philadelphia , Pa : Churchill Livingstone; 2003: 790.

Jason LA, Corradi K, et al. Chronic fatigue syndrome: the need for subtypes. *Neuropsychol Rev* . 2005 Mar;15(1):29–58.

Judy W. Presentation to the 37th Annual Meeting of the American College of Nutrition. Southeastern Institute Research.1996.

Kasper DL, Braunwald E, et al. *Harrison's Principles of Internal Medicine* . 16th ed. New York : McGraw-Hill; 2005.

Kelly GS. L-carnitine: therapeutic applications of a conditionally-essential amino acid. *Altern Med Rev* . 1998 Oct;3(5):345–60.

Kingsbury KJ. Plasma amino acid patterns in elite athletes. *Br J Sports Med* . 1998a Sep;32(3):266–7.

Kingsbury KJ, Kay L, et al. Contrasting plasma free amino acid patterns in elite athletes: association with fatigue and infection. *Br J Sports Med* . 1998b Mar;32(1):25–32.

Kuratsune H, Yamaguti K, et al. Dehydroepiandrosterone sulfate deficiency in chronic fatigue syndrome. *Int J Mol Med* . 1998 Jan;1(1):143–6.

Logan AC, Wong C. Chronic fatigue syndrome: oxidative stress and dietary modifications. *Altern Med Rev* . 2001 Oct;6(5):450–9.

Patarca R. Cytokines and chronic fatigue syndrome. *Ann N Y Acad Sci* . 2001 Mar;933:185–200.

Plioplys AV, Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. *Neuropsychobiology* . 1995;32(3):132–8.

Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. *Neuropsychobiology* . 1997;35(1):16–23.

Richards RS, Roberts TK, et al. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic

fatigue syndrome. *Redox Rep* . 2000;5(1):35–41.

Scott LV , Dinan TG. The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis. *Func Neurol* . 1999a Jan;14(1):3–11.

Scott LV, Salahuddin F, et al. Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health. *J Affect Disord* . 1999b Jul;54(1–2):129–37.

Smirnova IV, Pall ML. Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. *Mol Cell Biochem* . 2003 Jun;248(1–2):93–5.

Stejskal VD, Danersund A, et al. Metal-specific lymphocytes: biomarkers of sensitivity in man. *Neuroendocrinol Lett* . 1999;20(5):289–98.

Streeten DH, Anderson GH, Jr. The role of delayed orthostatic hypotension in the pathogenesis of chronic fatigue. *Clin Auton Res* . 1998 Apr;8(2):119–24.

Tirelli U, Marotta G, et al. Immunological abnormalities in patients with chronic fatigue syndrome. *Scand J Immunol* . 1994 Dec;40(6):601–8.

Tomoda A, Joudoi T, et al. Cytokine production and modulation: comparison of patients with chronic fatigue syndrome and normal controls. *Psychiatry Res* . 2005 Mar 30;134(1):101–4.

Ur E, White PD, et al. Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome. *Eur Arch Psychiatry Clin Neurosci* . 1992;241(5):317–22.

van Rensburg SJ, Potocnik FC, et al. Serum concentrations of some metals and steroids in patients with chronic fatigue syndrome with reference to neurological and cognitive abnormalities. *Brain Res Bull* . 2001 May 15;55(2):319–25.

Vecchiet J, Cipollone F, et al. Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. *Neurosci Lett* . 2003 Jan 2;335(3):151–4.

Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. *Psychosom Med* . 2004 Mar-Apr;66(2):276-82.

Vernon SD , Reeves WC. Evaluation of autoantibodies to common and neuronal cell antigens in chronic fatigue syndrome. *J Autoimmune Dis* . 2005 May 25;2(1):5.

Visser J, Blauw B, et al. CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone. *J Infect Dis* . 1998 Feb;177(2):451–4.

Vollmer-Conna U, Lloyd A, et al. Chronic fatigue syndrome: an immunological perspective. *Aust N Z J Psychiatry* . 1998 Aug;32(4):523–7.

Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. *Altern Med Rev* . 2000 Apr;5(2):93–108.

All Contents Copyright © 1995-2009 Life Extension Foundation All rights reserved.

LifeExtension®

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.